Editors:
- comparison of HBV and HCV in one volume
- comprehensive overview of epidemiology, molecular biology, immunology, and therapy
- international and well-known authorship
Part of the book series: Milestones in Drug Therapy (MDT)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (11 chapters)
-
Front Matter
-
Back Matter
About this book
Chronic viral hepatitis has emerged as one of the most common causes of disease and death worldwide. Because of their unique modes of replication and intimate association with the host immune system, hepatitis B virus (HBV) and hepatitis C virus (HCV) pose challenging problems to scientists in basic and applied research as well as to clinicians engaged in disease management. Although approved antiviral therapy is available for chronic HBV, the emergence of viral resistance provides a rationale for the development of novel chemotherapeutic agents. The lack of a robust cell culture system for HCV replication and a readily accessible small-animal model of HCV infection have hampered the development of antiviral agents for HCV. Neverthe-less, new antiviral agents targeting HCV are now in preclinical and clinical development.
This monograph, providing an up-to-date overview of the field of Hepatitis Prevention and Treatment, includes contributions from internationally recognized experts in the field of viral hepatitis, and covers the current state of knowledge and practice regarding the molecular biology, immunology, biochemistry, pharmacology and clinical aspects of chronic HBV and HCV infection. The volume includes salient topics such as: the history and epidemiology of HBV and HCV; recent insights into the molecular mechanisms of viral replication; the host immune response to infection and a discussion of the use (HBV) or potential development (HCV) of vaccines; the current standard of care for chronically-infected patients; and emerging therapies and issues associated with current antiviral treatments. The latest information to researchers and clinicians actively engaged in viral hepatitis research is provided, but also sufficient background and discussion of the literature to benefit the newcomer to the field.
Editors and Affiliations
-
PTC Therapeutics, Drug Discovery, South Plainfield, USA
Joseph M. Colacino
-
Eli Lilly and Company, Discovery Research, Indianapolis, USA
Beverly A. Heinz
Bibliographic Information
Book Title: Hepatitis Prevention and Treatment
Editors: Joseph M. Colacino, Beverly A. Heinz
Series Title: Milestones in Drug Therapy
DOI: https://doi.org/10.1007/978-3-0348-7903-3
Publisher: Birkhäuser Basel
-
eBook Packages: Springer Book Archive
Copyright Information: Springer Basel AG 2004
Hardcover ISBN: 978-3-7643-5956-0Published: 25 October 2004
Softcover ISBN: 978-3-0348-9617-7Published: 30 October 2012
eBook ISBN: 978-3-0348-7903-3Published: 06 December 2012
Series ISSN: 2296-6056
Series E-ISSN: 2296-6064
Edition Number: 1
Number of Pages: XI, 246
Topics: Pharmacology/Toxicology, Immunology, Medical Microbiology, Virology, Infectious Diseases